Immune Biomarkers for Predictability of Preeclampsia Clinical Scenarios

Volume 4 - Issue 1

Ahmed Hagras¹* and Maha MHagras²

Received:September 03, 2019;   Published: September 30, 2019

DOI: 10.32474/IGWHC.2018.04.000176

Full Text PDF

To view the Full Article   Peer-reviewed Article PDF

Abstract

Background: Preeclampsia a chief clinical scenario in obstetric medicine, having highly morbid and grave sequalae particularly if rapidly progressive and left unmanaged. The complexity of immune system components involvement is integrated in the preeclampsia pathology as immune based pathology is one of the cornerstone theories for preeclampsia development that have raised the issue that immune dysfunction affection is an issue that could be investigated in recent research efforts to reveal any immunological biomarker that could be implemented as a predictability tool for preeclampsia development and severity.

Aim: To investigate the possible usage of immune biomarkers in prediction of preeclampsia..

Methodology: The current study was conducted at Departments of Obstetrics & Gynecology and Clinical Pathology, Tanta University Hospitals. A prospective clinical research trial that involved cases having an ongoing gestation below 16 gestational weeks of with maternal age range of 18 to 40 years old were recruited in the current research study. During the study period, a total of 200 research study subjects. Peripheral blood was collected between 5th and 16th gestational weeks calculating the gestational age based on the last menstrual period and crown-rump length using a first trimester sonographic scan cases were clinically and investigationally followed till time of delivery and clinical research data was collected and tabulated for analysis the following was conducted on collected blood samples.

Results: The comparative statistical analysis women with and without pre-eclampsia regarding Serum levels (pg/ml) of cytokines and chemokines in which there was no statistical significant difference between both research groups as regards EGF, EOTAXING-CSF,GM-CSF ,IFN ALPHA 2,IFN-GAMMA , IL-10, IL-12p40, IL-12p70, IL-13, IL-15, IL17-A, IL-1RA, IL-1 alpha, IL-1 beta, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IP-10, MIP-1 beta, TNF- alpha, TNF-beta, VEGF (p values=0.812, 0.315, 0.712, 0.635, 0.511, 0.865, 0.829, 0.873, 0.603, 0.807, 0.865, 0.512, 0.925, 0.812, 0.512,0.310,0.423 ,0.478, 0.829, 0.903 ,0.865, 0.314, 0.885, 0.489,0.958,0.288 consecutively) however there was highly statistically significantly higher levels of IL-8 among the preeclampsia research group, and statically significantly higher levels of MCP-1 among no preeclampsia research group (p value= 0.012), whereas there was statically significantly higher levels of MIP-1 alpha among preeclampsia research group (p value= 0.032).

Conclusion: The current study findings denote that there is a possible clinical value in using immune biomarkers in preeclampsia screening, however future research efforts are required to verify the current study results in order to elucidate more clearly the most useful immune cell ratios and inflammatory mediators that could be clinically applicable and useful with the highest sensitivity in order to upgrade the management protocols of preeclampsia.

Abstract| Introduction| Methodology| Statistical Analysis| Results| Discussion| Conclusions and Recommendations| References|